Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor

Xu Bao Shi, Lingru Xue, Donghua Shi, Ralph W deVere White

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The androgen receptor (AR) acting as a transcription factor plays a pivotal role in the occurrence and progression of prostate cancer (CaP). Several AR-related factors or modulators have been reported to influence AR activity. Whether and how these factors cooperatively modulate the AR activity has not been well defined. In the present study, the combined effect of p160 coactivators, short CAG length (encoding a short polyQ tract), and AR mutations on AR transactivation in a yeast system was evaluated. It was found that the short polyQ tract can upregulate the transactivation of the wild-type (WT) AR and partial-function (PF) AR mutants in response to a physiological level (10 -9 M) of dihydrotestosterone. Addition of a p160 coactivator (SRC-1 or TIF2) to the above systems resulted in a significant increase in the ligand-stimulated transactivation. Although the androgen antagonist bicalutamide could suppress the activity of androgen-activated WT or PF ARs, it was unable to do so for gain-of-function AR mutants. A combination of the short polyQ tract and coactivator TIF2 acted cooperatively on the WT AR and PF AR mutants to enhance their transactivation in response to either a low level of dihydrotestosterone (10 -10 M) or adrenal dehydroepiandrosterone. Taken together, this finding suggests that the modulated AR activity may involve early in the carcinogenesis of CaP. Additionally, these data support the concept that a given CaP in which the AR activity is modulated by multiple AR modulators may progress more readily to castrate resistance.

Original languageEnglish (US)
Pages (from-to)191-201
Number of pages11
JournalCancer Biotherapy and Radiopharmaceuticals
Volume26
Issue number2
DOIs
StatePublished - Apr 1 2011

Fingerprint

Androgen Receptors
Transcriptional Activation
Dihydrotestosterone
polyglutamine
Androgen Antagonists
Dehydroepiandrosterone
Androgens
Prostatic Neoplasms
Carcinogenesis
Transcription Factors
Up-Regulation
Yeasts

Keywords

  • androgen receptor
  • prostate cancer
  • yeast assay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor. / Shi, Xu Bao; Xue, Lingru; Shi, Donghua; deVere White, Ralph W.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 26, No. 2, 01.04.2011, p. 191-201.

Research output: Contribution to journalArticle

@article{048faaa3e30b47c487f3f3861030b09c,
title = "Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor",
abstract = "The androgen receptor (AR) acting as a transcription factor plays a pivotal role in the occurrence and progression of prostate cancer (CaP). Several AR-related factors or modulators have been reported to influence AR activity. Whether and how these factors cooperatively modulate the AR activity has not been well defined. In the present study, the combined effect of p160 coactivators, short CAG length (encoding a short polyQ tract), and AR mutations on AR transactivation in a yeast system was evaluated. It was found that the short polyQ tract can upregulate the transactivation of the wild-type (WT) AR and partial-function (PF) AR mutants in response to a physiological level (10 -9 M) of dihydrotestosterone. Addition of a p160 coactivator (SRC-1 or TIF2) to the above systems resulted in a significant increase in the ligand-stimulated transactivation. Although the androgen antagonist bicalutamide could suppress the activity of androgen-activated WT or PF ARs, it was unable to do so for gain-of-function AR mutants. A combination of the short polyQ tract and coactivator TIF2 acted cooperatively on the WT AR and PF AR mutants to enhance their transactivation in response to either a low level of dihydrotestosterone (10 -10 M) or adrenal dehydroepiandrosterone. Taken together, this finding suggests that the modulated AR activity may involve early in the carcinogenesis of CaP. Additionally, these data support the concept that a given CaP in which the AR activity is modulated by multiple AR modulators may progress more readily to castrate resistance.",
keywords = "androgen receptor, prostate cancer, yeast assay",
author = "Shi, {Xu Bao} and Lingru Xue and Donghua Shi and {deVere White}, {Ralph W}",
year = "2011",
month = "4",
day = "1",
doi = "10.1089/cbr.2010.0888",
language = "English (US)",
volume = "26",
pages = "191--201",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor

AU - Shi, Xu Bao

AU - Xue, Lingru

AU - Shi, Donghua

AU - deVere White, Ralph W

PY - 2011/4/1

Y1 - 2011/4/1

N2 - The androgen receptor (AR) acting as a transcription factor plays a pivotal role in the occurrence and progression of prostate cancer (CaP). Several AR-related factors or modulators have been reported to influence AR activity. Whether and how these factors cooperatively modulate the AR activity has not been well defined. In the present study, the combined effect of p160 coactivators, short CAG length (encoding a short polyQ tract), and AR mutations on AR transactivation in a yeast system was evaluated. It was found that the short polyQ tract can upregulate the transactivation of the wild-type (WT) AR and partial-function (PF) AR mutants in response to a physiological level (10 -9 M) of dihydrotestosterone. Addition of a p160 coactivator (SRC-1 or TIF2) to the above systems resulted in a significant increase in the ligand-stimulated transactivation. Although the androgen antagonist bicalutamide could suppress the activity of androgen-activated WT or PF ARs, it was unable to do so for gain-of-function AR mutants. A combination of the short polyQ tract and coactivator TIF2 acted cooperatively on the WT AR and PF AR mutants to enhance their transactivation in response to either a low level of dihydrotestosterone (10 -10 M) or adrenal dehydroepiandrosterone. Taken together, this finding suggests that the modulated AR activity may involve early in the carcinogenesis of CaP. Additionally, these data support the concept that a given CaP in which the AR activity is modulated by multiple AR modulators may progress more readily to castrate resistance.

AB - The androgen receptor (AR) acting as a transcription factor plays a pivotal role in the occurrence and progression of prostate cancer (CaP). Several AR-related factors or modulators have been reported to influence AR activity. Whether and how these factors cooperatively modulate the AR activity has not been well defined. In the present study, the combined effect of p160 coactivators, short CAG length (encoding a short polyQ tract), and AR mutations on AR transactivation in a yeast system was evaluated. It was found that the short polyQ tract can upregulate the transactivation of the wild-type (WT) AR and partial-function (PF) AR mutants in response to a physiological level (10 -9 M) of dihydrotestosterone. Addition of a p160 coactivator (SRC-1 or TIF2) to the above systems resulted in a significant increase in the ligand-stimulated transactivation. Although the androgen antagonist bicalutamide could suppress the activity of androgen-activated WT or PF ARs, it was unable to do so for gain-of-function AR mutants. A combination of the short polyQ tract and coactivator TIF2 acted cooperatively on the WT AR and PF AR mutants to enhance their transactivation in response to either a low level of dihydrotestosterone (10 -10 M) or adrenal dehydroepiandrosterone. Taken together, this finding suggests that the modulated AR activity may involve early in the carcinogenesis of CaP. Additionally, these data support the concept that a given CaP in which the AR activity is modulated by multiple AR modulators may progress more readily to castrate resistance.

KW - androgen receptor

KW - prostate cancer

KW - yeast assay

UR - http://www.scopus.com/inward/record.url?scp=79955910089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955910089&partnerID=8YFLogxK

U2 - 10.1089/cbr.2010.0888

DO - 10.1089/cbr.2010.0888

M3 - Article

C2 - 21539451

AN - SCOPUS:79955910089

VL - 26

SP - 191

EP - 201

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 2

ER -